Ontology highlight
ABSTRACT:
SUBMITTER: de Castro Carpeno J
PROVIDER: S-EPMC4369862 | biostudies-literature | 2013 Apr
REPOSITORIES: biostudies-literature
de Castro Carpeño Javier J Belda-Iniesta Cristóbal C
Translational lung cancer research 20130401 2
K-RAS accounts for 90% of RAS mutations in lung adenocarcinomas, the most commonly mutated oncogene in NSCLC, with mutations detected in about 25% of all tumors. Direct inhibition of KRAS has proven clinically challenging. So far, no successful targeted therapy has been developed and remains an elusive target for cancer therapy. Despite significant efforts, currently there are no drugs directly targeting mutated KRAS. Thus, new strategies have emerged for targeting RAS including the use of synth ...[more]